Blueprint Medicines Corp [BPMC] stock prices are up 4.14% to $116.32 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BPMC shares have gain 7.92% over the last week, with a monthly amount glided 9.92%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Blueprint Medicines Corp [NASDAQ: BPMC] stock has seen the most recent analyst activity on May 14, 2024, when Stephens initiated its Overweight rating and assigned the stock a price target of $140. Previously, Leerink Partners upgraded its rating to Market Perform on May 06, 2024, and elevated its price target to $97. On October 27, 2023, upgrade upgraded it’s rating to Outperform but maintained its price target of $85 on the stock. Needham reiterated its Buy rating and increased its price target to $66 on August 21, 2023. Wells Fargo upgraded its rating to a Overweight and raised its price target to $82 on July 31, 2023. SVB Securities downgraded its rating to Underperform for this stock on June 05, 2023, and downed its price target to $43. In a note dated January 03, 2023, Wells Fargo upgraded an Equal Weight rating on this stock but restated the target price of $41.
The stock price of Blueprint Medicines Corp [BPMC] has been fluctuating between $43.89 and $111.99 over the past year. Currently, Wall Street analysts expect the stock to reach $100.73 within the next 12 months. Blueprint Medicines Corp [NASDAQ: BPMC] shares were valued at $116.32 at the most recent close of the market. An investor can expect a potential drop of -13.4% based on the average BPMC price forecast.
Analyzing the BPMC fundamentals
The Blueprint Medicines Corp [NASDAQ:BPMC] reported sales of 282.21M for trailing twelve months, representing a surge of 51.87%. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -1.56%, Pretax Profit Margin comes in at -1.02%, and Net Profit Margin reading is -1.02%. To continue investigating profitability, this company’s Return on Assets is posted at -0.28, Equity is -1.21 and Total Capital is -0.53. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.67.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 112.91 points at the first support level, and at 109.50 for the second support level. However, for the 1st resistance point, the stock is sitting at 119.51, and for the 2nd resistance point, it is at 122.71.
Ratios To Look Out For
It’s worth pointing out that Blueprint Medicines Corp [NASDAQ:BPMC]’s Current Ratio is 3.76. As well, the Quick Ratio is 3.61, while the Cash Ratio is 0.55. Considering the valuation of this stock, the price to sales ratio is 25.81, the price to book ratio is 23.44.
Transactions by insiders
Recent insider trading involved Durso-Bumpus Debra, CHIEF PEOPLE OFFICER, that happened on Jul 05 ’24 when 3850.0 shares were sold. CHIEF PEOPLE OFFICER, Durso-Bumpus Debra completed a deal on Jul 03 ’24 to sell 8817.0 shares. Meanwhile, CHIEF PEOPLE OFFICER Durso-Bumpus Debra sold 333.0 shares on Jun 28 ’24.
